MedPath

Effects of Canagliflozin on microbiota and glycometabolism, kidney function of patients with diabetic nephropathy

Not Applicable
Completed
Conditions
diabetic nephropathy
Registration Number
JPRN-UMIN000020710
Lead Sponsor
Keio University, School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
33
Inclusion Criteria

Not provided

Exclusion Criteria

1.patiens whose eGFR declined more than 25% during the observation period 2.patients with fasting blood glucose higher than 250mg/dl 3.patients who has been on dialysis or who went through renal transplantation 4.patients with type 1 diabetes or secondary diabetes 5.patients who has taken other investigational drugs within 3months of the beginning of this study 6.patients who fall under contraindication of Canagliflozin 7.patients whom the doctor decided unsuitable for the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
the microbiome of patients with diabetic nephropaty
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath